Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +1.24%8 Current Ratio is 3.99 as of Dec. 2025, which is 23% below its 10-year median of 5.21. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 69.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alamar Biosciences's current ratio for the quarter that ended in Dec. 2025 was 3.99.
Alamar Biosciences has a current ratio of 3.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Alamar Biosciences's Current Ratio or its related term are showing as below:
ALMR'
s Current Ratio Range Over the Past 10 Years
Min: 3.99 Med: 5.21 Max: 6.43
Current: 3.99
During the past 2 years, Alamar Biosciences's highest Current Ratio was 6.43. The lowest was 3.99. And the median was 5.21.
ALMR's Current Ratio is ranked better than 69.64% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs ALMR: 3.99
Alamar Biosciences (NAS:ALMR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Alamar Biosciences Current Ratio Related Terms
Alamar Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Current Ratio Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Current Ratio
6.43
3.99
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Current Ratio
6.43
3.99
ALMR vs UFPT, BFLY, ENOV: Current Ratio Comparison
For the Medical Devices subindustry, Alamar Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Current Ratio of 3.99 as of Dec. 2025. This is 23% below median its historical median of 5.21. Over the past decade, Alamar Biosciences' Current Ratio has ranged from 3.99 to 6.43. According to the industry distribution chart, Alamar Biosciences ranks #259 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 30.4%.
Is Alamar Biosciences' Current Ratio too high?
Alamar Biosciences' current Current Ratio of 3.99 is 23% below median its 10-year median of 5.21. Over the past 10 years, this metric has ranged from a low of 3.99 to a high of 6.43. The Medical Devices & Instruments industry median Current Ratio is 2.49. Alamar Biosciences' value of 3.99 is 60.2% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #259 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Current Ratio compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #259 out of 853 companies for Current Ratio. This puts Alamar Biosciences in the upper half of its industry. The industry median Current Ratio is 2.49. Alamar Biosciences' value of 3.99 is 60.2% above this benchmark. Historically, Alamar Biosciences' own Current Ratio has ranged from 3.99 to 6.43 over the past decade. While the company's 10-year median is 5.21 vs. the industry median of 2.49, Alamar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Current Ratio of 3.99 is 60.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Current Ratio is 3.99, which is 23% below median its own 10-year median of 5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Current Ratio of 3.99. The current Current Ratio is 3.99, which is 23% below median its 10-year median of 5.21 and 60.2% above the Medical Devices & Instruments industry median of 2.49. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Current Ratio is 3.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
